Table 2.
Baseline Demographics
| Treatment Sequence AB n = 14 | Treatment Sequence BA n = 13 | Total N = 27 | |
|---|---|---|---|
| Age, y | |||
| Median (range) | 32 (20‐43) | 26 (19‐43) | 30 (19‐43) |
| Mean (SD) | 31 (7.2) | 29 (7.6) | 30 (7.3) |
| Sex, n (%) | |||
| Female | 14 (100) | 12 (92.3) | 26 (96.3) |
| Male | 0 | 1 (7.7) | 1 (3.7) |
| Race, n (%) | |||
| Asian | 0 | 1 (7.7) | 1 (3.7) |
| Black or African American | 3 (21.4) | 2 (15.4) | 5 (18.5) |
| White | 10 (71.4) | 9 (69.2) | 19 (70.4) |
| Other | 1 (7.1) | 1 (7.7) | 2 (7.4) |
| Ethnicity, n (%) | |||
| Hispanic or Latino | 0 | 1 (7.7) | 1 (3.7) |
| Not Hispanic or Latino | 14 (100) | 12 (92.3) | 26 (96.3) |
| Body weight, kg | |||
| Median (range) | 65.6 (54.6‐90.9) | 72.2 (55.6‐84.5) | 67.8 (54.6‐90.9) |
| Mean (SD) | 68.1 (9.70) | 70.7 (9.39) | 69.4 (9.46) |
| Body mass index, kg/m2 | |||
| Median (range) | 24.7 (19.3‐29.8) | 26.1 (19.2‐29.1) | 24.8 (19.2‐29.8) |
| Mean (SD) | 25.1 (3.07) | 25.4 (3.01) | 25.3 (2.99) |
SD, standard deviation.
Percentages based on total number of participants in the safety analysis set. Treatment A was a single dose of atorvastatin 40 mg, followed by a 1‐day washout and a single dose of pravastatin 40 mg/rosuvastatin 10 mg; treatment B was filgotinib 200 mg once daily for 11 days, atorvastatin 40 mg on day 6, followed by pravastatin 40 mg/rosuvastatin 10 mg on day 8.